Keyphrases
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
78%
Type 2 Diabetic Patients
71%
Type 2 Diabetes Mellitus (T2DM)
45%
National Cohort Study
41%
Dipeptidyl peptidase-4 (DPP-4)
33%
South Korea
29%
Taiwan
19%
Randomized Controlled Trial
19%
Emulation
19%
Diabetes Analysis
19%
Cardiovascular Outcome Trials
19%
Antidiabetic Drugs
19%
Safety Outcomes
19%
Seizure
19%
Acute Heart Failure
19%
Meta-analysis
19%
Cardiovascular Safety
19%
Autism Spectrum Disorder
19%
Case-case
19%
Amputation
19%
Discharge Outcomes
19%
Diuretic Use
19%
Adverse Respiratory Events
19%
Attention Deficit Hyperactivity Disorder
19%
Metformin
19%
Evogliptin
19%
Cardiovascular Disease
19%
Tramadol Use
19%
Oral Corticosteroids
19%
Tramadol
19%
Case-time-control
19%
Atopic Dermatitis
19%
Systematic Meta-analysis
19%
Dual Therapy
19%
Triple Therapy
19%
Antipsychotics
19%
Angiotensin Receptor-neprilysin Inhibitor
19%
Heart Failure Admission
19%
Target Trial Emulation
19%
Adjusted Odds Ratio
19%
Confidence Interval
19%
Hazard Ratio
17%
Adverse Events
16%
Propensity Score Matching
15%
Heart Failure
11%
Sulfonylurea
9%
Myocardial Infarction
9%
Heart Failure Readmission
8%
Cardiovascular Mortality
8%
Individual Outcomes
8%
Medicine and Dentistry
Sodium-Glucose Cotransporter 2 Inhibitors
78%
Patient with Type 2 Diabetes
67%
Cohort Analysis
61%
Congestive Heart Failure
43%
Sodium Glucose Cotransporter 2 Inhibitor
39%
Dipeptidyl Peptidase-4 Inhibitor
33%
Maturity Onset Diabetes of the Young
26%
Cardiovascular System
23%
Hazard Ratio
21%
Acute Decompensated Heart Failure
19%
Cardiovascular Disease
19%
Attention Deficit Disorder
19%
Amputation
19%
Evogliptin
19%
Atopic Dermatitis
19%
Tramadol
19%
Glycon
19%
Pervasive Developmental Disorder
19%
Meta-Analysis
19%
Systematic Review
19%
Epileptic Seizure
19%
Enkephalinase Inhibitor
19%
Angiotensin Receptor
19%
Diuretics
19%
Antipsychotic
19%
Oral
19%
Adverse Event
16%
Odds Ratio
14%
Respiratory Physiology
14%
Proportional Hazards Model
10%
Sulfonylurea
9%
Acute Respiratory Distress Syndrome
9%
Respiratory Failure
9%
Pulmonary Edema
9%
Primary Outcome
9%
Myocardial Infarction
9%
Clinician
6%
Propensity Score Matching
6%
Dose Response
5%
Pharmacology, Toxicology and Pharmaceutical Science
Maturity Onset Diabetes of the Young
100%
sodium glucose cotransporter-2 inhibitors
78%
Cohort Study
61%
Congestive Heart Failure
44%
Sodium Glucose Cotransporter 2 Inhibitor
39%
Dipeptidyl Peptidase IV Inhibitor
33%
Randomized Controlled Trial
19%
Antidiabetic Agent
19%
Antipsychotic
19%
Tramadol
19%
Evogliptin
19%
Adverse Event
19%
Acute Heart Failure
19%
Atopic Dermatitis
19%
Metformin
19%
Attention Deficit Disorder
19%
Enkephalinase Inhibitor
19%
Diuretics
19%
Angiotensin Receptor
19%
Cardiovascular Disease
19%
Sulfonylurea
9%
Lung Edema
9%
Adult Respiratory Distress Syndrome
9%
Respiratory Failure
9%
Heart Infarction
9%